Lonza Group

Lonza Group is a Swiss multinational company and a global leader in providing products and services to the pharmaceutical industry, biotechnology, and nutrition markets. Founded in the late 19th century, the company has evolved from a regional hydroelectricity producer into a premier contract development and manufacturing organization (CDMO). Its operations are critical in the supply chain for novel therapeutics, including mRNA vaccines, cell therapy, and small molecule APIs.

History

The company's origins trace back to 1897 with the establishment of a hydroelectric power plant on the Lonza River in the Canton of Valais. Initially focused on electrochemistry and carbide production, it later expanded into chemical intermediates for industries like textiles and plastics. A pivotal shift occurred in the late 20th century when leadership, including former Ciba-Geigy executive Robert G. Fleming, steered the firm toward life sciences. Major acquisitions, such as the cell culture business from Whittaker Corporation and the biologics site in Portsmouth from Genentech, solidified its biopharmaceutical capabilities. The COVID-19 pandemic marked a significant chapter, as Lonza partnered with Moderna to manufacture key components for their mRNA-1273 vaccine at facilities in Visp and Georgetown.

Business segments

Lonza operates through two primary reporting segments: Biologics and Small Molecules, and Cell and Gene. The Biologics and Small Molecules segment encompasses services for large molecule therapeutics, including monoclonal antibodies and recombinant proteins, as well as chemical synthesis for small molecule APIs and pharmaceutical intermediates. The Cell and Gene segment focuses on advanced therapies, providing development and manufacturing for cell therapy products, viral vectors used in gene therapy, and mRNA-based technologies. Additionally, a dedicated Microbial Control division serves the consumer health and industrial preservation markets with sanitizers and antimicrobial solutions.

Products and services

The company's portfolio is centered on contract manufacturing and development services for the life sciences sector. Key offerings include the production of biologic drug substances, fill and finish operations for sterile vials, and comprehensive support for clinical trial material. It is a major producer of cell culture media and feeds through its Gibco-branded products, essential for bioreactor processes. For cell and gene therapy innovators, Lonza provides plasmids, adeno-associated virus vectors, and autologous cell processing platforms like the Cocoon Platform. Its chemical synthesis expertise supports the entire drug development pipeline, from non-GMP kilolab quantities to commercial-scale API manufacturing.

Operations and facilities

Lonza maintains a global network of cGMP-compliant facilities across North America, Europe, and Asia. Major sites include large-scale mammalian cell culture plants in Slough, Swiss sites in Visp and Basel, and a significant biologics campus in Porriño, Spain. In the United States, key operations are located in Portsmouth, Houston, and Walkersville. The Singapore facility serves the Asia-Pacific region for biologics manufacturing. Each site is specialized; for instance, Georgetown focuses on mRNA, Kourou in French Guiana produces plasmids, and Bend is dedicated to viral vector development. The company invests heavily in capacity expansion projects, such as the major build-out in Basel.

Corporate affairs

Lonza is publicly traded on the SIX Swiss Exchange under the symbol "LONN". Its governance is led by a Board of Directors chaired by Albert M. Baehny, with Pierre-Alain Ruffieux serving as Chief Executive Officer. The company emphasizes environmental, social, and corporate governance (ESG) goals, targeting carbon neutrality for its operations by 2050 and promoting diversity and inclusion initiatives. It engages in numerous strategic partnerships with entities like Moderna, Sanofi, and AstraZeneca, and collaborates with research institutions including the Massachusetts Institute of Technology and the University of Oxford. Corporate headquarters are located in Basel, within the Swiss chemical and pharmaceutical industry hub.

Category:Companies listed on the SIX Swiss Exchange Category:Pharmaceutical companies of Switzerland Category:Biotechnology companies Category:Companies based in Basel